Rani Therapeutics Holdings, Inc. RANI
We take great care to ensure that the data presented and summarized in this overview for Rani Therapeutics Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RANI
View all-
Armistice Capital, LLC New York, NY2.57MShares$4.09 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA710KShares$1.13 Million0.0% of portfolio
-
Nan Fung Group Holdings LTD Central, K3494KShares$784,7981.04% of portfolio
-
Alphabet Inc. Mountain View, CA448KShares$713,1020.07% of portfolio
-
United Services Automobile Association San Antonio, TX303KShares$481,3610.02% of portfolio
-
Stifel Financial Corp St. Louis, MO270KShares$428,9310.0% of portfolio
-
Geode Capital Management, LLC Boston, MA172KShares$273,8940.0% of portfolio
-
Northern Trust Corp Chicago, IL106KShares$167,9580.0% of portfolio
-
King Luther Capital Management Corp Fort Worth, TX81.1KShares$128,9950.0% of portfolio
-
Bank Of America Corp Charlotte, NC76.1KShares$121,0700.0% of portfolio
Latest Institutional Activity in RANI
Top Purchases
Top Sells
About RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Insider Transactions at RANI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2024
|
Kate Mc Kinley Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
17,960
+50.0%
|
$17,960
$1.67 P/Share
|
|
Dec 09
2024
|
Talat Imran Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,296
+2.04%
|
$10,296
$1.94 P/Share
|
|
Oct 15
2024
|
South Cone Investments Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,829,360
-16.59%
|
$7,658,720
$2.91 P/Share
|
|
Dec 06
2023
|
Talat Imran Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+2.02%
|
$20,000
$2.27 P/Share
|
|
Dec 04
2023
|
Talat Imran Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+1.04%
|
$10,000
$2.57 P/Share
|
|
Nov 29
2023
|
Talat Imran Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+4.09%
|
$40,000
$2.05 P/Share
|
|
Nov 24
2023
|
South Cone Investments Limited Partnership > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
5,265,165
+30.27%
|
$10,530,330
$2.01 P/Share
|
|
Nov 24
2023
|
Cortes Isidoro Alfonso Quiroga > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,265,165
-99.84%
|
$10,530,330
$2.01 P/Share
|
|
Nov 17
2023
|
Jean Luc Butel |
BUY
Open market or private purchase
|
Direct |
50,500
+50.0%
|
$101,000
$2.03 P/Share
|
|
Nov 16
2023
|
Maulik Nanavaty |
BUY
Open market or private purchase
|
Direct |
500
+50.0%
|
$500
$1.98 P/Share
|
|
Nov 07
2023
|
Talat Imran Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.55%
|
$5,000
$2.0 P/Share
|
|
May 12
2023
|
South Cone Investments Limited Partnership > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,645
+0.04%
|
$7,935
$3.98 P/Share
|
|
May 11
2023
|
South Cone Investments Limited Partnership > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,610
+0.04%
|
$7,830
$3.87 P/Share
|
|
May 08
2023
|
South Cone Investments Limited Partnership > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,420
+0.06%
|
$17,680
$4.46 P/Share
|
|
May 03
2023
|
South Cone Investments Limited Partnership > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,040
+0.03%
|
$8,160
$4.81 P/Share
|
|
Apr 28
2023
|
South Cone Investments Limited Partnership > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,173
+0.03%
|
$8,692
$4.71 P/Share
|
|
Apr 25
2023
|
South Cone Investments Limited Partnership > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,423
+0.06%
|
$17,692
$4.51 P/Share
|
|
Apr 24
2023
|
South Cone Investments Limited Partnership > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,280
+0.06%
|
$17,120
$4.67 P/Share
|
|
Apr 21
2023
|
South Cone Investments Limited Partnership > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,100
+0.06%
|
$16,400
$4.93 P/Share
|
|
Apr 20
2023
|
South Cone Investments Limited Partnership > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,850
+0.03%
|
$9,250
$5.32 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 28.3K shares |
|---|
| Open market or private sale | 3.83M shares |
|---|